

Raphael J Landovitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3086054/publications.pdf>

Version: 2024-02-01

90
papers

4,907
citations

156536

32
h-index

111975

67
g-index

92
all docs

92
docs citations

92
times ranked

6320
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 500-506.	1.3	2
2	Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. <i>JAMA Network Open</i> , 2022, 5, e2142796.	2.8	57
3	Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States. <i>Annals of Internal Medicine</i> , 2022, 175, 479-489.	2.0	37
4	Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. <i>PLoS ONE</i> , 2022, 17, e0262926.	1.1	15
5	Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	0
6	Low Incidence and Prevalence of Hepatitis C in Two Cohorts of HIV Pre-Exposure Prophylaxis Adherence Interventions in Men Who Have Sex with Men in Southern California. <i>Journal of Viral Hepatitis</i> , 2022, , .	1.0	3
7	Promises and challenges: cabotegravir for preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 186-191.	1.5	7
8	Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e1927-e1935.	2.9	7
9	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Annals of Internal Medicine</i> , 2021, 174, 344-352.	2.0	73
10	Taking a stand against the politicization of medical research: how "swinging the pendulum" poses a hazard to clinical trials, study participants, and the progress of science. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 101-103.	1.3	1
11	Assessing the Role of Long-Acting Cabotegravir Preexposure Prophylaxis of Human Immunodeficiency Virus: Opportunities and Aspirations. <i>Journal of Infectious Diseases</i> , 2021, 223, 1-3.	1.9	5
12	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. <i>Journal of Infectious Diseases</i> , 2021, 224, 1581-1592.	1.9	72
13	Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, 1149-1156.	2.9	15
14	Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1585-1595.	1.0	10
15	Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. <i>Lancet HIV</i> , 2021, 8, e723-e728.	2.1	3
16	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608.	13.9	359
17	COVID-19 Vaccine Decision-making Factors in Racial and Ethnic Minority Communities in Los Angeles, California. <i>JAMA Network Open</i> , 2021, 4, e2127582.	2.8	108
18	Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 226-239.	2.5	2

#	ARTICLE	IF	CITATIONS
19	Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project. <i>AIDS Patient Care and STDs</i> , 2021, 35, 481-487.	1.1	5
20	Challenges and Opportunities for Preexposure Prophylaxis. <i>Topics in Antiviral Medicine</i> , 2021, 29, 399-406.	0.1	2
21	Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. <i>Clinical Infectious Diseases</i> , 2020, 70, 687-691.	2.9	22
22	Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. <i>Clinical Infectious Diseases</i> , 2020, 70, 319-322.	2.9	31
23	HIV Preexposure Prophylaxis—The Role of Primary Care Clinicians in Ending the HIV Epidemic. <i>JAMA Internal Medicine</i> , 2020, 180, 126.	2.6	11
24	Long-acting injectable cabotegravir for the prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 19-26.	1.5	71
25	PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa329.	0.4	3
26	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1651.	3.8	329
27	Donate now to prevent sexually transmitted infections later: incentivising testing of sexually transmitted infections. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 885-886.	4.6	0
28	Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 93-97.	0.9	9
29	Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. <i>AIDS and Behavior</i> , 2020, 24, 2520-2531.	1.4	41
30	Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. <i>Lancet HIV</i> , the, 2020, 7, e472-e481.	2.1	97
31	Novel Antiretroviral Agents. <i>Current HIV/AIDS Reports</i> , 2020, 17, 118-124.	1.1	23
32	Collective Call to Action for HIV/AIDS Community-Based Collaborative Science in the Era of COVID-19. <i>AIDS and Behavior</i> , 2020, 24, 2013-2016.	1.4	26
33	Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART. <i>PLoS ONE</i> , 2019, 14, e0219802.	1.1	3
34	Long term surgical outcomes for infective endocarditis in people who inject drugs: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2019, 19, 918.	1.3	32
35	Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. <i>Lancet HIV</i> , the, 2019, 6, e788-e799.	2.1	79
36	Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals. <i>Current HIV/AIDS Reports</i> , 2019, 16, 349-358.	1.1	47

#	ARTICLE	IF	CITATIONS
37	Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1228-1233.	0.6	17
38	Complex decisions: correlates of injectable contraceptive discontinuation following HIV-1 seroconversion in an HIV prevention trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 746-753.	0.6	0
39	Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions. <i>Journal of the International AIDS Society</i> , 2019, 22, e25247.	1.2	15
40	Factors associated with repeat rectal <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> screening following inconclusive nucleic acid amplification testing: A potential missed opportunity for screening. <i>PLoS ONE</i> , 2019, 14, e0226413.	1.1	1
41	Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1044-1047.	2.9	22
42	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. <i>Aids</i> , 2019, 33, 237-246.	1.0	17
43	Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 421-429.	0.5	13
44	Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? A case-crossover study of men who have sex with men in Los Angeles, California. <i>Sexually Transmitted Infections</i> , 2018, 94, 457-462.	0.8	60
45	Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir. <i>Clinical Infectious Diseases</i> , 2018, 67, 791-794.	2.9	27
46	Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County. <i>International Journal of STD and AIDS</i> , 2018, 29, 557-562.	0.5	6
47	Sexually Transmitted Infection Testing of HIV-Positive Medicare and Medicaid Enrollees Falls Short of Guidelines. <i>Sexually Transmitted Diseases</i> , 2018, 45, 8-13.	0.8	25
48	Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002690.	3.9	126
49	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 379.	3.8	486
50	Acceptability of Injectable and On-Demand Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in California. <i>LGBT Health</i> , 2018, 5, 341-349.	1.8	19
51	PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw525.	1.9	40
52	Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 501-511.	0.9	60
53	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	2.0	29
54	An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 21-29.	0.9	235

#	ARTICLE	IF	CITATIONS
55	Contingent Vs. Non-Contingent Rewards: Time-Based Intervention Response Patterns Among Stimulant-Using Men Who Have Sex With Men. <i>Journal of Substance Abuse Treatment</i> , 2017, 72, 19-24.	1.5	8
56	Antiretroviral Therapy: Racial Disparities among Publicly Insured Californians with HIV. <i>Journal of Health Care for the Poor and Underserved</i> , 2017, 28, 406-429.	0.4	11
57	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 191.	3.8	533
58	The promise and pitfalls of long-acting injectable agents for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 122-128.	1.5	91
59	Individual-Level, Partnership-Level, and Sexual Event-Level Predictors of Condom Use During Receptive Anal Intercourse Among HIV-Negative Men Who Have Sex with Men in Los Angeles. <i>AIDS and Behavior</i> , 2016, 20, 1315-1326.	1.4	23
60	Quality of Care for HIV/AIDS and for Primary Prevention by HIV Specialists and Nonspecialists. <i>AIDS Patient Care and STDs</i> , 2016, 30, 395-408.	1.1	21
61	HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. <i>AIDS and Behavior</i> , 2016, 20, 2983-2995.	1.4	5
62	Optimizing Delivery of Preexposure Prophylaxis—The Next Frontier. <i>JAMA Internal Medicine</i> , 2016, 176, 85.	2.6	5
63	Three Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. <i>Annals of Internal Medicine</i> , 2015, 162, 461-462.	2.0	3
64	Benefits of PrEP as an Adjunctive Method of HIV Prevention During Attempted Conception Between HIV-uninfected Women and HIV-infected Male Partners. <i>Journal of Infectious Diseases</i> , 2015, 212, 1534-1543.	1.9	22
65	Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv085.	0.4	19
66	Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles. <i>International Journal of STD and AIDS</i> , 2015, 26, 1040-1048.	0.5	70
67	Contingency Management Facilitates the Use of Postexposure Prophylaxis Among Stimulant-Using Men Who Have Sex With Men. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofu114.	0.4	19
68	Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257. <i>Clinical Infectious Diseases</i> , 2015, 60, 1842-1851.	2.9	67
69	Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation. <i>Topics in Antiviral Medicine</i> , 2015, 23, 85-90.	0.1	13
70	Uptake and Repeat Use of Postexposure Prophylaxis in a Community-Based Clinic in Los Angeles, California. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 848-855.	0.5	14
71	Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. <i>Annals of Internal Medicine</i> , 2014, 161, 461.	2.0	225
72	Moving HIV PrEP from research into practice. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 781-783.	4.6	3

#	ARTICLE	IF	CITATIONS
73	Commercial lubricant use among HIV-negative men who have sex with men in Los Angeles: implications for the development of rectal microbicides for HIV prevention. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1609-1618.	0.6	12
74	Online Social Networking, Sexual Risk and Protective Behaviors: Considerations for Clinicians and Researchers. <i>Current Addiction Reports</i> , 2014, 1, 220-228.	1.6	67
75	Two years of Truvada for pre-exposure prophylaxis utilization in the US. <i>Journal of the International AIDS Society</i> , 2014, 17, 19730.	1.2	59
76	Epidemiology, Sexual Risk Behavior, and HIV Prevention Practices of Men who Have Sex with Men Using GRINDR in Los Angeles, California. <i>Journal of Urban Health</i> , 2013, 90, 729-739.	1.8	245
77	Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. <i>Aids</i> , 2013, 27, 1119-1128.	1.0	2
78	High-Risk Sexual Behavior Is Associated with Postexposure Prophylaxis Nonadherence among Men Who Have Sex with Men Enrolled in a Combination Prevention Intervention. <i>Journal of Sexually Transmitted Diseases</i> , 2013, 2013, 1-7.	1.0	9
79	Sexual Risk Behaviors and Acceptability of HIV Pre-Exposure Prophylaxis Among HIV-Negative Gay and Bisexual Men in Serodiscordant Relationships: A Mixed Methods Study. <i>AIDS Patient Care and STDs</i> , 2012, 26, 87-94.	1.1	161
80	A Novel Combination HIV Prevention Strategy: Post-Exposure Prophylaxis with Contingency Management for Substance Abuse Treatment Among Methamphetamine-Using Men Who Have Sex with Men. <i>AIDS Patient Care and STDs</i> , 2012, 26, 320-328.	1.1	35
81	Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 1136-1145.	0.6	132
82	Preexposure Prophylaxis for HIV Prevention. <i>Current HIV/AIDS Reports</i> , 2011, 8, 94-103.	1.1	45
83	Aching for a diagnosis. <i>Journal of Hospital Medicine</i> , 2010, 5, 55-59.	0.7	0
84	Availability of HIV Postexposure Prophylaxis Services in Los Angeles County. <i>Clinical Infectious Diseases</i> , 2009, 48, 1624-1627.	2.9	15
85	Postexposure Prophylaxis for HIV Infection. <i>New England Journal of Medicine</i> , 2009, 361, 1768-1775.	13.9	76
86	Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-Naive Subjects with HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2008, 198, 1113-1122.	1.9	71
87	Postexposure prophylaxis after sexual exposure to HIV. <i>Future HIV Therapy</i> , 2007, 1, 35-47.	0.5	3
88	Recent efforts in biomedical prevention of HIV. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2007, 15, 99-103.	2.9	9
89	Symptomatic Junctional Bradycardia After Treatment with Nelfinavir. <i>Clinical Infectious Diseases</i> , 1999, 29, 449-450.	2.9	8
90	Engagement with HIV and COVID-19 prevention: a national cross-sectional analysis of users on a geosocial networking app (Preprint). <i>Journal of Medical Internet Research</i> , 0, , .	2.1	0